edoxaban

Also Known As:

DU-176; DU-176b; N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide; N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate; Savaysa; edoxaban tosylate

Networked: 1039 relevant articles (102 outcomes, 361 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lip, Gregory Y H: 61 articles (10/2022 - 01/2012)
2.	Giugliano, Robert P: 56 articles (09/2022 - 10/2010)
3.	Ruff, Christian T: 51 articles (09/2022 - 10/2010)
4.	Antman, Elliott M: 47 articles (09/2022 - 10/2010)
5.	Braunwald, Eugene: 41 articles (09/2022 - 10/2010)
6.	Mercuri, Michele F: 30 articles (01/2021 - 06/2015)
7.	De Caterina, Raffaele: 28 articles (10/2022 - 09/2013)
8.	Murphy, Sabina A: 26 articles (09/2022 - 11/2013)
9.	Shi, Minggao: 25 articles (01/2022 - 09/2010)
10.	Weitz, Jeffrey I: 23 articles (09/2022 - 09/2010)

Related Diseases

1.	Hemorrhage 01/01/2022 - "Although treatment with edoxaban was highly effective in preventing VTE recurrence, its administration should be cautiously considered because of the high bleeding rate. " 10/01/2014 - "Although rapidly cleared, strategies to reverse edoxaban-mediated effects on anticoagulation are needed in cases of excessive bleeding or emergency. " 11/15/2023 - "In this study, the highly risky drug Edoxaban (EDX), which can threaten life and cause bleeding, was electro analytically evaluated. " 01/01/2023 - "This study aimed to investigate the association between SLCO1B1 gene polymorphisms and the bleeding risk in patients receiving edoxaban. " 01/01/2022 - "During the study period, 20 and 11 major bleeding events occurred in the edoxaban and placebo groups, respectively. "
2.	Atrial Fibrillation 12/12/2022 - "The aim of this study was to assess the safety and efficacy of on-label reduced-dose edoxaban in patients with atrial fibrillation (AF). " 08/01/2023 - "The real-world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA-AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. " 08/01/2023 - "Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients." 01/01/2022 - "Methods and Results This was a prespecified subanalysis of the on-treatment analysis set of the ELDERCARE-AF (Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients) trial. " 01/01/2022 - "To examine the effects of very low-dose edoxaban (15 mg) vs placebo across 3 age strata (80-84 years, 85-89 years, and ≥90 years) among patients with AF who were a part of the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial. "
3.	Stroke (Strokes) 11/02/2023 - "Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study." 01/01/2023 - "The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinical and real-world studies. " 01/01/2022 - "Patients with AF, being treated with edoxaban for stroke prevention will be included in this study. " 09/13/2021 - "Therefore, in the current study we aimed to assess in a clinically relevant setting whether treatment with edoxaban attenuates stroke severity, and whether edoxaban has an impact on the local cerebral inflammatory response and blood-brain barrier (BBB) function after experimental IS in mice. " 02/03/2021 - "The Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program integrates prospective, observational, noninterventional regional studies from Europe, Japan, and other Asian countries, collecting data on patient characteristics and clinical outcomes in unselected patients treated with edoxaban for stroke prevention in AF. "
4.	Venous Thromboembolism 08/01/2021 - "In the treatment of venous thromboembolism in adults, edoxaban has shown to be effective and safe.This" 01/01/2022 - "Previous preliminary clinical trials have confirmed that edoxaban can be efficacious for venous thromboembolism (VTE). " 02/06/2020 - "Background: ETNA-VTE-Japan is a prospective, observational study conducted as part of a postmarketing study regarding the safety and effectiveness of edoxaban in Japanese patients with venous thromboembolism (VTE). " 01/01/2018 - "Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study." 01/01/2018 - "Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study."
5.	Neoplasms (Cancer) 04/01/2022 - "Conclusion Our study, conducted on a real world population of patients with cancer-associated VTE, confirms the results of randomized controlled clinical trials, and supports the use of edoxaban as effective and safe treatment in this context." 12/25/2017 - "Conclusion: Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy." 03/01/2021 - "Lower-weight-based dosing is supported by cancer-specific studies such as half-dose edoxaban in the Hokusai-VTE cancer trial in individuals weighing <60 kg. " 01/01/2021 - "The present paper focuses on the role of edoxaban in VTE treatment, from general population to cancer patients, presenting the available data from randomized clinical trials and real world, to discuss edoxaban use in clinical practice." 01/01/2018 - "Among the trials, ENGAGE AF-TIMI 48 provides more data on the efficacy and safety of edoxaban in cancer patients."

Related Drugs and Biologics

1.	Warfarin (Coumadin)
2.	apixaban
3.	Anticoagulants
4.	Rivaroxaban
5.	Dabigatran
6.	Creatinine
7.	Vitamin K
8.	Factor Xa Inhibitors
9.	Heparin (Liquaemin)
10.	Aspirin (Acetylsalicylic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Catheter Ablation
3.	Drug Tapering
4.	Percutaneous Coronary Intervention
5.	Knee Replacement Arthroplasty (Total Knee Replacement)